Central & Eastern Europe Research Institute

What Central & Eastern Europe Research Institute does

Central & Eastern Europe Research Institute (CEERI) is a privately held, Romania-headquartered clinical research organization (CRO) and site management organization (SMO) founded in 2004 that operates a clinical trial delivery network spanning 20+ Central and Eastern European countries, with 500+ affiliated hospitals and clinics, 2,000+ investigative personnel, and access to a combined population of 350M+. The company delivers end-to-end clinical research services including site selection and management, regulatory affairs, clinical monitoring, data management and biostatistics (CDISC SDTM/ADaM), pharmacovigilance (100,000+ cases annually), medical writing, bioequivalence and Phase I studies (1,200+ conducted), and clinical research staffing and training. CEERI's flagship assets include the Rapid Start-up Network for accelerated site activation, 15+ Therapeutic Centers of Expertise, a Vaccine Research Site Network covering 30+ countries, and dedicated Clinical Research Centers in Warsaw, Bucharest, and Turkey.

Through its wholly owned subsidiary Avicenna Cell & Gene Therapy Center (ACGTC), CEERI has expanded into advanced therapy development with 7 CGT centers across Turkey, Tunisia, and Saudi Arabia, offering mRNA-LNP, CAR-T/NK, antibody engineering, viral vector production, gene editing (CRISPR-Cas9), stem cell, and exosome-based therapy capabilities. Revenue is generated through project-based professional services contracts with pharmaceutical companies, biotechnology firms, and other CROs; pricing is not publicly disclosed. Customer concentration is concentrated in B2B enterprise relationships with notable past partnerships on COVID-19 vaccine trials with Pfizer-BioNTech, Sinovac Biotech, and Gamaleya Research Institute, plus a mutual partnership with Turkey's TUSEB. The company is governed by an Operational Committee and Medical Steering Committee comprising senior academic clinicians, and operates functional offices in Romania, Turkey, Serbia, and Poland.

Name

Central & Eastern Europe Research Institute

Legal name

Central & Eastern Europe Research Institute

Website

https://cee-ri.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

CEERI is a privately held Romania-based CRO/SMO operating a network of 500+ hospitals across 20+ CEE countries, delivering end-to-end clinical trial services — site management, biostatistics, pharmacovigilance, and bioequivalence studies — to pharmaceutical, biotech, and CRO clients, with an ACGTC subsidiary expanding into cell and gene therapy across MENA.

Ownership category

akta.pro rank

Product category

Clinical Research Services (Contract Research Organization)

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Clinical research services
• Contract research organization
• Clinical trial management
• Site management organization
• Biostatistics and pharmacovigilance

Headquarters

HQ city

Bucharest

HQ country

Romania

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. Clinical Development Program Management: Comprehensive clinical trial management services including study design, execution, monitoring, and closeout support for pharmaceutical companies, biotech firms, and CROs.
2. Clinical Research Staffing: Staffing services providing sponsors and CROs with clinical research coordinators, research nurses, CRAs, regulatory specialists, and other clinical operations personnel through contract, temporary-to-hire, and direct hire arrangements.
3. Site Management Services: Management of clinical research sites including site selection, feasibility, activation, and ongoing site management services.
4. Regulatory Affairs Services: Strategic and operational regulatory support including regulatory intelligence, global consulting, product lifecycle management, and regulatory documentation submissions.
5. Data Management & Biostatistics: Drug safety, data management, medical writing, project management, and biostatistics support services ensuring compliance and quality in clinical trials.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

CEERI operates as a Contract Research Organization (CRO) and Site Management Organization delivering end-to-end clinical trial support across Central and Eastern Europe, including clinical development program management, regulatory affairs, drug safety and data management, medical writing, biostatistics, project and trial management, site management, clinical research staffing, and bioequivalence/Phase I services. Through its ACGTC subsidiary, CEERI offers specialized cell and gene therapy CRO/CDMO services (mRNA-LNP, CAR-T/NK, antibody engineering, viral vectors, stem cell therapies). The organization is supported by a 500+ hospital and clinic network spanning 20+ CEE countries, with access to a combined population of over 350 million.

Product overview

CEERI operates as a comprehensive clinical research organization offering an integrated platform of services across Central & Eastern Europe. The core portfolio includes the Rapid Start-up Network (500+ hospitals), Therapeutic Centers of Expertise (15+ specialized centers), Clinical Research Centers, and a dedicated Bioequivalence and Phase One Unit. The subsidiary brand ACGTC (Avicenna Cell & Gene Therapy Center) provides advanced cell and gene therapy services including mRNA-LNP development, CAR-T/NK therapy, and antibody engineering. Supporting services include IT Solutions (biostatistics, data management, pharmacovigilance), staffing services, staff training, and the Vaccine Research Site Network. The company serves pharmaceutical companies, biotech firms, and CROs across 20+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• ACGTC (Avicenna Cell & Gene Therapy Center): Specialized cell and gene therapy research center providing end-to-end support for development and commercialization of innovative cell and gene therapies, including mRNA-LNP, CAR-T/NK, antibody engineering, viral vectors, stem cell therapies, and regenerative medicine.

Products and services

• Rapid Start-up Network A turnkey network of 500+ hospitals and clinics across 20 Central and Eastern European countries that accelerates clinical trial initiation through rapid site selection, feasibility, and activation for sponsors and CROs.
• Therapeutic Centers of Expertise 15+ specialized Therapeutic Centers of Expertise covering Cardiovascular, Oncology, CNS, Infectious Diseases, Metabolic Diseases, Pediatric, and other areas to enhance clinical trial support and execution.
• Avicenna Cell & Gene Therapy Center (ACGTC) End-to-end cell and gene therapy development and commercialization support including mRNA-LNP, CAR-T/NK, antibody engineering, viral vectors, stem cell therapies, regenerative medicine, gene editing, and exosome-based therapies; delivered through 7 CGT centers in Turkey, Tunisia, and Saudi Arabia.
• Bioequivalence and Phase One Unit Dedicated Phase I and bioequivalence unit conducting early-phase studies including SAD/MAD, bioequivalence studies, food-effect, drug-drug interaction, and Phase 1a/1b studies; ~1,200+ early phase and bioequivalence studies and 20,000+ patients/volunteers handled.
• Clinical Research Centers (CRCs) Advanced clinical research centers with state-of-the-art labs, early-phase units, and full-service trial capabilities located in Warsaw (10 hospitals/clinics), Bucharest (9 hospitals/clinics), and Turkey (14 hospitals/clinics).
• Staffing Services Clinical research staffing services supplying sponsors and CROs with clinical research coordinators, research nurses, CRAs, regulatory specialists, and other clinical operations personnel through contract, temporary-to-hire, and direct hire arrangements.
• Staff Training Training management system providing additional certifications and skill development tailored to project requirements, with screening processes including background checks and credential verification for clinical research staff.
• IT Solutions End-to-end IT services for clinical trials including Statistical Programming & Biostatistics (CDISC SDTM/ADaM, TLF, DMC/DSMB analysis), Clinical Data Management (CRF/eCRF, query management, medical coding), Pharmacovigilance (100,000+ cases annually), and Clinical Software Development (web, CRM/ERP, mobile apps).
• Vaccine Research Site Network Global alliance of clinical investigation sites across CEE, MENA, SEA, and GCC regions for vaccine research, spanning 30+ countries, 1,000+ medical facilities, 4,000+ investigators, and 200,000+ participants enrolled, with proven pandemic response experience across H1N1, MERS, Zika, and COVID-19.
• Clinical Research Services Full-service CRO offering spanning Clinical Development Program Management, Regulatory Affairs (intelligence, consulting, submissions, lifecycle management), Drug Safety & Data Management (safety reporting, database construction, data standardization), Medical Writing (CERs/CEPs, SSCPs, literature reviews), Project & Trial Management, and Biostatistics for sponsors and CROs.
• mRNA-LNP Development Completely validated mRNA-LNP platform for formulation and manufacturing, with focus on cardiometabolic diseases including heart disease, diabetes, and obesity.
• CAR-T/NK Development CRO/CDMO services covering early discovery through clinical trials for CAR-T cell therapy, providing comprehensive care from patient evaluation to long-term follow-up.
• Antibody Engineering & Production Therapeutic and diagnostic antibody development including protein engineering, production in microbial and mammalian systems, antibody discovery via phage/yeast display, and characterization.
• Gene Editing Technologies Advanced gene editing capabilities including CRISPR-Cas9 for ex vivo and in vivo gene therapies, along with non-viral delivery systems such as electroporation, nanoparticles, and liposomes.
• Stem Cell Therapies iPSC development, HSC therapies for blood cancers and immune disorders, and ocular stem cell therapies for eye diseases.
• Viral Vector Production Production of AAV vectors, lentiviral vectors for CAR-T therapies, and retroviral vectors for ex vivo gene modification.
• Exosome-Based Therapies Engineering exosomes for delivery of therapeutic molecules including RNA, proteins, and drugs as an emerging therapeutic modality.

Quantifiable outcome

• 1,200+ Early Phase & Bioequivalence Studies Conducted
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered major and core.

• Pfizer-BioNTechmajorStrategic or Co-development PartnerCEERI Vaccine Research Site Network collaborated with Pfizer-BioNTech on COVID-19 vaccine studies during the pandemic response effort. This partnership contributed to the global fight against COVID-19 through clinical trial execution.
• Sinovac BiotechmajorStrategic or Co-development PartnerCEERI worked with Sinovac Biotech on vaccine studies as part of their pandemic response and vaccine development efforts across the CEE network.
• Gamaleya Research InstitutemajorStrategic or Co-development PartnerCEERI collaborated with Gamaleya Research Institute on vaccine studies, supporting their COVID-19 vaccine development through clinical trial operations.
• Health Institutes of Turkey (TUSEB)coreStrategic or Co-development PartnerCEERI partnered with TUSEB on vaccine studies in Turkey, leveraging local regulatory expertise and site capabilities for pandemic response clinical trials.

Scale indicators16 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IQVIA: Largest global CRO/commercial services firm offering full-service clinical operations, data, and consulting across all regions including CEE. Competes with CEERI for multi-region pharma and biotech sponsors, though at much greater scale.
• ICON plc: Top-3 global CRO offering Phase I–IV services, biometrics, and labs with strong European footprint including Central Europe. Competes head-to-head with CEERI for European-anchored trial programs.
• Parexel International: Global full-service CRO with broad therapeutic-area coverage and significant European site-network relationships. Direct overlap with CEERI's clinical operations and regulatory offerings.
• Medpace: Mid-to-large global CRO known for full-service Phase II–III execution across multiple therapeutic areas. Comparable in clinical operations and biostatistics service mix to CEERI.
• Syneos Health: Global biopharmaceutical services organization combining CRO and commercial capabilities. Overlaps with CEERI on clinical monitoring, biostatistics, and pharmacovigilance services.
• Charles River Laboratories: Large CRO/preclinical services firm with biostatistics, data management, and bioanalytical capabilities overlapping with CEERI's data/biostatistics and pharmacovigilance offerings.

Direct peers

• Ergomed: Specialty CRO with strong European footprint and expertise in oncology and rare disease clinical research, including site management and pharmacovigilance services — closely comparable in service mix and regional focus to CEERI.
• PSI CRO: European-headquartered, mid-sized full-service CRO with operations across multiple CEE and CIS countries. Closely comparable in size, regional focus, and full-service clinical offerings.

Emerging players

• Worldwide Clinical Trials: Mid-sized global CRO focused on complex Phase II–III trials in CNS, cardiometabolic, and rare disease — therapeutic areas where CEERI also claims centers of expertise.
• Clinipace Worldwide: Mid-sized CRO with European/Central European operations providing full-service clinical research, biostatistics, and regulatory affairs — comparable scale and service profile to CEERI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ceeri-research

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Central & Eastern Europe Research Institute